'''Eletriptan''' (brand name '''Relpax''', used in the form of eletriptan hydrobromide) is a second generation [[triptan]] [[medication]] intended for treatment of [[migraine]] [[headache]]s. It is used as an [[abortive medication]], blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by [[Pfizer|Pfizer Inc]]. It is sold in the United States and Canada under the brand name Relpax, and in several other countries under the brand name '''Relert'''.
'''Eletriptan''' (brand name '''Relpax''', used in the form of eletriptan hydrobromide) is a second generation [[triptan]] [[medication]] intended for treatment of [[migraine]] [[headache]]s. It is used as an [[abortive medication]], blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by [[Pfizer|Pfizer Inc]].
==Approval and availability==
==Approval and availability==
Eletriptan was approved by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) on December 26, 2002, for the acute treatment of migraine with or without [[Aura (symptom)|aura]] in adults.<ref name=accessdata>FDA AccessData entry for [http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020763&TABLE1=OB_Rx Eletriptan Hydrobromide], accessed March 10, 2010.</ref> It is available only by [[Medical prescription|prescription]] in the [[United States]] and [[Canada]]. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. It is available in 20 mg and 40 mg strengths.
Eletriptan was approved by the US [[Food and Drug Administration]] (FDA) on December 26, 2002, for the acute treatment of migraine with or without [[Aura (symptom)|aura]] in adults.<ref name=accessdata>FDA AccessData entry for [http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020763&TABLE1=OB_Rx Eletriptan Hydrobromide], accessed March 10, 2010.</ref> It is available only by [[Medical prescription|prescription]] in the United States and Canada. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. It is available in 20 mg and 40 mg strengths.
Eletriptan was covered by {{US patent|5545644|U.S. Patent no. 5545644}}<ref name=accessdata/><ref>{{US patent|5545644|U.S. Patent no. 5545644}}, John E. Macor & Martin J. Wythes, ''Indole Derivatives'', August 13, 1996.</ref> and {{US patent|6110940|U.S. Patent no. 6110940}};<ref name=accessdata/><ref>{{US patent|6110940|U.S. Patent no. 6110940}}, Valerie Denise Harding, ''et al.'', ''Salts of an anti-migraine indole derivative'', August 29, 2000.</ref> both now expired.
Eletriptan was covered by {{US patent|5545644|U.S. Patent no. 5545644}}<ref name=accessdata/><ref>{{US patent|5545644|U.S. Patent no. 5545644}}, John E. Macor & Martin J. Wythes, ''Indole Derivatives'', August 13, 1996.</ref> and {{US patent|6110940|U.S. Patent no. 6110940}};<ref name=accessdata/><ref>{{US patent|6110940|U.S. Patent no. 6110940}}, Valerie Denise Harding, ''et al.'', ''Salts of an anti-migraine indole derivative'', August 29, 2000.</ref> both now expired.
Eletriptan (brand name Relpax, used in the form of eletriptan hydrobromide) is a second generation triptanmedication intended for treatment of migraineheadaches. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc.
Approval and availability
Eletriptan was approved by the US Food and Drug Administration (FDA) on December 26, 2002, for the acute treatment of migraine with or without aura in adults.[1] It is available only by prescription in the United States and Canada. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. It is available in 20 mg and 40 mg strengths.
Eletriptan is believed to reduce swelling of the blood vessels surrounding the brain. This swelling is associated with the head pain of a migraine attack. Eletriptan blocks the release of substances from nerve endings that cause more pain and other symptoms like nausea, and sensitivity to light and sound. It is thought that these actions contribute to relief of symptoms by eletriptan.
Eletriptan has no significant affinity or pharmacological activity at adrenergicα1, α2, or β; dopaminergicD1 or D2; muscarinic; or opioid receptors. Eletriptan could be efficiently co-administrated with nitric oxide synthase (NOS's) inhibitors for the treatment of NOS-dependent diseases (US patent US 2007/0254940).
Two theories have been proposed to explain the efficacy of 5-HT1 receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Side effects
Common side effects include hypertension, tachycardia, headache, dizziness, drowsiness and symptoms similar to angina pectoris. Severe allergic reactions are rare.[4]
Contraindications
Eletriptan is contraindicated in patients with various diseases of the heart and circulatory system, such as angina pectoris, severe hypertension, and heart failure, as well as in patients that have had a stroke or heart attack. This is due to the unusual side effect of coronary vasoconstriction due to serotonin 5HT1B antagonism, which can precipitate a heart attack in those already at risk. It is also contraindicated in severe renal or hepatic impairment due to its extensive liver metabolism through CYP3A4.[4]
Interactions
Strong inhibitors of the liver enzyme CYP3A4, such as erythromycin and ketoconazole, significantly increase blood plasma concentration of eletriptan and should be separated by at least 72 hours. Ergot alkaloids, such as dihydroergotamine, add to the drug's hypertensive effect and should be separated by at least 24 hours.[4]
(what is this?) (verify)
